Building a Sustainable Growth Company

Transcription

1 Building a Sustainable Growth Company 1

2 Safe Harbor Statement This presentation contains forward-looking information that involves risks and uncertainties, including statements about the Company s plans, objectives, expectations and intentions. Such statements include, without limitation: financial or other information based upon or otherwise incorporating judgments or estimates relating to future performance, events or expectations; the Company s strategies, positioning, resources, capabilities and expectations for future performance; and the Company's outlook and financial and other guidance. These statements are based upon assumptions made by the Company as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from expectations. Risks and uncertainties that could adversely affect the Company s business and prospects, and otherwise cause actual results to differ materially from those anticipated, include, without limitation: the ability of the Company to successfully manage leadership and organizational changes, including the ability of the Company to attract, motivate and retain key employees; U.S., European and worldwide economic conditions and related uncertainties; the Company s reliance on third party reimbursement policies to support the sales and market acceptance of its products, including the possible adverse impact of government regulation and changes in the availability and amount of reimbursement and uncertainties for new products or product enhancements; uncertainties regarding healthcare reform legislation, including associated tax provisions, or budget reduction or other cost containment efforts; changes in guidelines, recommendations and studies published by various organizations that could affect the use of the Company s products; uncertainties inherent in the development of new products and the enhancement of existing products, including FDA approval and/or clearance and other regulatory risks, technical risks, cost overruns and delays; the risk that products may contain undetected errors or defects or otherwise not perform as anticipated; risks associated with strategic alliances and the ability of the Company to realize anticipated benefits of those alliances; risks associated with acquisitions, including, without limitation, the Company s ability to successfully integrate acquired businesses, the risks that the acquired businesses may not operate as effectively and efficiently as expected even if otherwise successfully integrated; the risks that acquisitions may involve unexpected costs or unexpected liabilities; the risks of conducting business internationally, including the effect of exchange rate fluctuations on those operations; manufacturing risks, including the Company s reliance on a single or limited source of supply for key components, and the need to comply with especially high standards for the manufacture of many of its products and risks associated with utilizing third party manufacturers; the Company s ability to predict accurately the demand for its products, and products under development, and to develop strategies to address its markets successfully; the early stage of market development for certain of the Company s products; the Company s leverage risks, including the Company s obligation to meet payment obligations and financial covenants associated with its debt; risks related to the use and protection of intellectual property; expenses, uncertainties and potential liabilities relating to litigation, including, without limitation, commercial, intellectual property, employment and product liability litigation; technical innovations that could render products marketed or under development by the Company obsolete; competition; and the Company s ability to attract and retain qualified personnel. The risks included above are not exhaustive. Other factors that could adversely affect the company's business and prospects are described in filings made with the SEC. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based. Hologic, Aptima, Aptima Combo 2, Genius, Horizon, MyoSure, NovaSure, Panther, Selenia, The Science of Sure, ThinPrep, Tigris and associated logos, as may be used in this presentation, are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries. Procleix is a trademark of Grifols Diagnostic Solutions Inc. 2

3 Non-GAAP Financial Measures Hologic has presented the following non-gaap financial measures in this presentation: revenues; gross margins; operating expenses; operating income; interest expense; pre-tax income; net income; EPS; and adjusted EBITDA. In this presentation, Hologic defines its non-gaap revenues to primarily include contingent revenue earned post-acquisition in FY13 under its blood screening collaboration that was eliminated under purchase accounting. Hologic defines adjusted EBITDA as its non-gaap net income plus net interest expense, income taxes, and depreciation and amortization expense included in its non-gaap net income. Hologic defines its non-gaap gross margins, operating expenses, operating income, interest expense, pre-tax income and EPS to exclude, as applicable: (i) the amortization of intangible assets and impairment of goodwill and intangible assets; (ii) acquisition-related charges and effects, such as charges for contingent consideration, transaction costs, integration costs including retention, and credits and/or charges associated with the write-up of acquired inventory and fixed assets to fair value, and the effect of a reduction in revenue related to contingent revenue under the Company s blood screening collaboration; (iii) non-cash interest expense related to amortization of the debt discount for the equity conversion option of convertible debt securities; (iv) restructuring and divestiture charges; (v) non-cash extinguishment losses and debt transaction costs; (vi) litigation settlement charges (benefits); (vii) otherthan-temporary impairment losses on investments; and (viii) other one-time, nonrecurring, unusual or infrequent charges, expenses or gains that may not be indicative of Hologic s core business results; and to include income taxes related to such adjustments. These non-gaap financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with GAAP. The company s definition of these non-gaap measures may differ from similarly titled measures used by others. The non-gaap financial measures used in this press release adjust for specified items that can be highly variable or difficult to predict. The company generally uses these non-gaap financial measures to facilitate management s financial and operational decision-making, including evaluation of Hologic s historical operating results, comparison to competitors operating results and determination of management incentive compensation. These non-gaap financial measures reflect an additional way of viewing aspects of the company s operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures, may provide a more complete understanding of factors and trends affecting Hologic s business. Because non-gaap financial measures exclude the effect of items that will increase or decrease the company s reported results of operations, management strongly encourages investors to review the company s consolidated financial statements and publicly filed reports in their entirety. A reconciliation of the non- GAAP financial measures to the most directly comparable GAAP financial measures is included in the tables accompanying this release. 3

4 Presentation Outline Hologic overview Accomplishments to date Future opportunities Financials and conclusion 4

5 Encouraging Progress in Turnaround U.S. businesses improving more rapidly than expected, with encouraging profit impact and growth potential Stabilizing mature franchises ThinPrep liquid cytology NovaSure for abnormal uterine bleeding Maximizing growth drivers Genius 3D Mammography in breast health Panther system in molecular diagnostics MyoSure in GYN surgical Strengthening the balance sheet 5

6 Hologic Today Innovative healthcare company with market-leading products for early detection and intervention, with a strong position in women s health Divisional Revenue FY15 Types of Revenue FY15 Diagnostics 45% Skeletal 4% Breast Health 39% Surgical 12% Service 16% Capital 23% Consumables 61% New management team leading transition from turnaround to sustainable growth FY15 revenue +8%* (+10% CC**) to $2,705 million; EPS +14%* to $1.67 Tremendous earnings power and cash flow generation 33.3% non-gaap operating margin, $697 million free cash flow in FY15 * Revenue and EPS growth exclude ~$20 million one-time contribution in 4Q14 from restructuring of Roka license, which added $0.05 to EPS. ** Constant currency growth. Data represents Hologic s 2015 fiscal year ending in September. 6

7 Evidence of the Turnaround Demonstrating consistent quarterly sales growth $700 $694 10% $703 10% $695 7% $650 $631 $613 $626 $622 $612 (3%) $625 2% $633 1% $640 3% $653 7% $655 5% $600 $550 (3%*) 2%* 1%* 3%* 8%* 7%* 12%* 12%* 8%* $ Q1 Q2 Q3 Q4 * Constant currency growth. ** Total GAAP revenue growth as reported with the exception of 4Q FY14, which excludes ~$20 million onetime contribution from restructuring of Roka license. Percentage changes versus prior year periods. 7

8 Broad, Deep Quarterly Sales Growth Dx Breast Surgical Skeletal Total US Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q Dx Breast Surgical Skeletal Total OUS Dx Breast Surgical Skeletal Worldwide 0-4.9% 5-9.9% 10%+ decline * Constant currency revenue change with the exception of 4Q FY14, which excludes ~ $20 million one-time contribution from restructuring of Roka license. 8

9 Future Opportunities for Sustainable Growth Continued growth from U.S. commercial execution, plus: R&D pipeline International expansion Operational efficiencies Tax Capital deployment 9

10 Presentation Outline Hologic overview Accomplishments to date Future opportunities Financials and conclusion 10

11 Sales Stabilizing Leading product for liquid Pap testing U.S. market share >75%* Headwinds from longer testing intervals Re-energized we love ThinPrep focus Domestic market share gains International penetration in early stages» Sales +4% in FY15; +10% in Q4* Future priorities Increase co-testing penetration Invest in marketing, R&D to revitalize brand Grow internationally $600 $500 $400 $300 Cytology & Perinatal Sales $556 $519 $485 $472 (7%*) (7%*) 1%* * Hologic estimate for the US market on a unit basis in Constant currency growth. 11

12 Sales Stabilizing Leading solution for abnormal uterine bleeding U.S. market share >65%* Better commercial execution Revitalized sales force» Improved incentive plans, lowered attrition» Expanded clinical specialists in field Global sales +2% in 2015* $300 $250 $200 $150 1%* $100 $259 NovaSure Sales $235 $219 $217 (9%*) (7%*) 2%* Future priorities Expand U.S. market versus alternative solutions Penetrate developed markets OUS * Hologic estimate for the US market on a unit basis in Constant currency growth. 12

13 Growth Driver: Innovative technology addresses limitations of conventional mammography $250 Breast Imaging Sales $234 $242 Landmark JAMA study Genius TM mammograms detected 41% more invasive breast cancers, while reducing recall rates by 15% $225 $200 $175 $178 $189 $193 $196 $197 $211 12%* 14%* 24%* 26%* Global breast imaging sales +19%* in FY15 Publication of clinical benefits High-impact marketing campaign CMS reimbursement Inferior competitive entrants $ Q1 Q2 Q3 Q4 * Constant currency growth. 13

14 Significant Opportunity for Continued Genius TM Growth U.S. market leader with ~60% share* Gained ~3 share points in FY15 Product advantages include superiority claim, faster scan time Customers ranked Hologic highest in all 11 measures in KLAS study** Significant U.S. market penetration still ahead as market upgrades to 3D Full conversion implies >$3.5 billion of future system sales Plus growing service annuity Two-year moratorium on implementing USPSTF recommendations Nascent international opportunity U.S. Penetration Metrics as of September 2015 HOLX 3D Installed Base HOLX 2D Installed Base Total Mammo Units HOLX 3D of HOLX Installed Base HOLX 3D of Total Market 2,400 6,200 14,500 ~28% ~17% * Hologic estimate for the US market on a unit basis in **Women s Imaging. Are the New Technologies Delivering Promised Benefits? August Performance Report KLAS Enterprises, LLC. All rights reserved. 14

15 System Driving Molecular Growth Panther system offers best-in-class automation and workflow More than 1,000 units in field globally #1 in CT/NG, HPV and Trich testing in U.S. Growing assay menu and utilization Average Panther system generated >$170,000 of revenue in FY15 U.S. molecular sales grew 9.5% in FY15** Future priorities Maximize Panther placements Drive adoption of current and future portfolio, including viral load assays Launch next-generation Panther Fusion Build international business $130 $120 $110 $100 $113 $113 Molecular Sales $116 $117 $119 $120 $125 $123 6%* 8%* 9%* 7%* Q1 Q2 Q3 Q4 * Constant currency growth. ** Excluding ~$20 million one-time contribution from restructuring of Roka license in 4QFY14. 15

16 Driving Growth in GYN Surgical Leading hysteroscopic tissue removal solution for fibroids and polyps $35 MyoSure Sales $32 $32 Grew 35% in FY15* Accelerated customer adoption and improved utilization both domestically and overseas $30 $25 $20 $20 $21 $23 $23 $25 $27 28%* 35%* 38%* 39%* Future priorities Continue broadening usage Maximize benefits of clinical specialists Expand internationally $ Q1 Q2 Q3 Q4 * Constant currency growth. 16

17 Strengthening the Balance Sheet Strong cash flows enabled significant improvements in FY15 Re-financed bank loan and high-yield bond» Lowered interest expense, increased financial flexibility Reduced total debt by $628 million» Voluntarily pre-paid $300 million of former term loan in Q1» Repurchased $300 million of 2010 convertible notes in Q4 Ended 1Q16 with net debt of $3.0 billion and leverage ratio of 3.1 x Targeting 2.5x by end of FY17 $5.0 $4.0 $3.0 $2.0 $1.0 $0.0 Net Debt and Leverage Ratio* $4.5 $ x $3.5 $3.1 $ x 4.0x 3.3x 3.1x Q16 * Net debt is total debt minus cash; leverage ratio is principal debt minus cash to TTM adjusted EBITDA. 17

18 Presentation Outline Hologic overview Accomplishments to date Future opportunities Financials and conclusion 18

19 Revitalizing Research and Development Committed to organic growth via shortand long-term R&D Upgrading talent and processes Focused on optimizing investment Key programs build on strong existing product and channel platforms Diagnostics» 3 Viral load assays, and assay for Mycoplasma genitalium detection all launched in Europe» Complementary women s health tests» Panther Fusion to provide new chemistry and assay format Breast health» Affirm prone biopsy table with 3D compatibility launching in FY16» Brevera next-generation biopsy device 19

20 International Opportunity Largely Untapped Only 24% of revenues generated OUS in FY15 Early signs of progress, but will take considerable time Key priorities Mammography Cytology» More than 24,000 units in 10 focus» More than 30 million liquid Pap tests in 10 markets, only 1/3 are 2D/3D focus markets, Hologic share only ~40%» Hologic share less than half of U.S. level» Plus more than 140 million conventional» Optimize distributor network and Pap tests relationships» And long-term opportunity to increase Molecular diagnostics adherence to screening» Panther well-suited to smaller, hospitalbased Surgical customers» More than 85% of business comes from» All three viral load assays recently CEmarked U.S. today» Continue executing on menu expansion 20

21 Multiple Opportunities to Increase Profitability Building on industry-leading margins Operational Improvements Realize efficiencies from higher U.S. sales volumes Achieve productivity goals across plant network Improve inventory management Implement central procurement Out-source Skeletal manufacturing Consolidate headquarters Leverage G&A expenses Tax Multi-faceted program underway Re-financing of bank debt loosened covenants In near-term, re-align legal entities and optimize product and transaction efficiencies First 100 basis points of improvement seen in 1Q16 Over long-term, migrate infrastructure and decisionmaking as OUS revenue grows Capital Deployment Priority remains to reduce debt, with focus on dilutive convertible notes Capability for tuck-in business development rebuilt in divisions Assess share repurchase over medium-term 21

22 Presentation Outline Hologic overview Accomplishments to date Future opportunities Financials and conclusion 22

23 Revenue Highlights 1Q Fiscal 2016 Revenue ($M) 1Q16 1Q15 Non-GAAP Reported Change CC Change Diagnostics $310.7 $ % 3.7% Breast Health $262.2 $ % 9.9% GYN Surgical $98.8 $ % 18.8% Skeletal Health $23.5 $ % 7.7% Total Revenue $695.2 $ % 8.1% US $545.1 $ % 12.8% OUS $150.0 $169.5 (11.5%) (5.4%) 23

24 Financial Overview 1Q Fiscal 2016 Non-GAAP In millions, except EPS 1Q16 Change vs. 1Q15 Revenues $ % Gross Margin 65.2% 190 bps Operating Expenses $ % Operating Margin 33.4% 50 bps Net Income $ % Diluted EPS $ % EBITDA $ % 24

25 2016 Financial Guidance Full Year (Non-GAAP*) 2Q (Non-GAAP*) In millions, except EPS 2016 Guidance Reported vs CC vs Q16 Guidance Reported vs CC vs Revenues $2,800 - $2, % % $ % % Diluted EPS $ $ % % $ $ % % *Guidance provided by press release on 1/27/16. Presentation here is not, and should not be construed as, re-affirmation of guidance. Guidance assumes diluted shares outstanding of million for the full year and an annual effective tax rate of approximately 33%. 25

26 Strong Growth in Annual Revenues and Profits $2,800 Revenue* $2,705 34% Operating Margin* 33.3% $1.70 EPS* $1.67 $2,600 $2,492 $2,511 32% 32.3% 32.0% $1.50 $1.50 $1.46 $2,400 30% $1.30 $2,200 $2,000 28% $ * Total GAAP revenue growth as reported with the exception of FY14, which excludes ~$20 million one-time revenue contribution from restructuring of Roka license that also increased operating margin and added $0.05 to EPS in FY14. Operating margin and EPS are non-gaap. 26

27 ROIC Steadily Improving Combination of increasing profits and lower debt 12.0% 11.0% 10.0% 9.3% 9.7% 10.0% 10.9% 10.6% 11.3% +160 bps vs. prior year 9.0% 8.2% 8.3% 8.3% 8.0% 7.0% 6.0% Q1 Q2 Q3 Q4 ROIC on a Trailing Twelve Month basis, defined as adjusted net operating profit after tax divided by average net debt plus stockholders equity. 27

28 Strong Cash Flows, Low Capital Intensity Focus on working capital efficiency paying off $275 $225 $175 FY15 EBITDA $972 million, +10%* FY15 FCF $697 million, +63% $125 $75 $25 Q1'14 Q2'14 Q3'14 Q4'14 Q1'15 Q2'15 Q3'15 Q4'15 EBITDA Op Cash Flow Free Cash Flow *FY15 EBITDA growth excludes ~$20 million one-time contribution from restructuring of Roka license. Free cash flow defined as operating cash flow minus capital expenditures. 28

29 A Bright Future Ahead We have accomplished a lot in a short amount of time Stabilizing mature businesses in the U.S. Maximizing domestic growth drivers Strengthening the balance sheet But we still have significant runway ahead of us R&D pipeline International expansion Operational efficiencies Tax Capital deployment As we transition from a turnaround story to a sustainable growth company With tremendous earnings power and cash generation capabilities 29

30 For more information: Michael Watts VP, Investor Relations and Corporate Communications

31 Financial Appendix 31

32 Overview of Hologic s Debt Senior Term Loan A $1.463 billion in annual payments over the next five years:» $75, $94, $131, $150 and $1,013 million» LIBOR % Revolving credit facility ($1.0 billion)» $175 million initially drawn 2% convertible notes $150 million (2010 notes) due 2037 (was $450 million prior to Q4 paydown)» Strike price of $23.03, callable in December 2016» Holders are eligible to convert as stock price exceeded 130% trigger ($29.94/share) $370 million (2013 notes) due 2043» Strike price of $38.59 callable in December 2017» 0% cash coupon; accretion 4% $500 million (2012 notes) due 2042» Strike price of $31.18 callable in March 2018 $1 billion senior notes due % interest 32

33 Business Segments Revenue Detail (unaudited) $s in millions Fiscal Year Q13 12/29/12 2Q13 3/30/13 3Q13 6/29/13 4Q13 9/28/13 Full Year % of Revenue Share Business Segment Revenues Cytology & Perinatal $137.0 $124.9 $132.2 $124.8 $ % Molecular Diagnostics % Blood Screening % Total Diagnostics $305.9 $296.5 $297.4 $290.0 $1, % Breast Imaging $173.8 $171.3 $182.9 $188.0 $ % Interventional Breast Solutions % Other % Total Breast Health $220.8 $220.1 $230.0 $234.2 $ % Surgical $80.9 $73.7 $75.8 $76.7 $ % Skeletal Health $23.7 $22.4 $22.9 $21.2 $ % Total Revenues $631.4 $612.7 $626.1 $622.1 $2,

34 Business Segments Revenue Detail (unaudited) $s in millions Business Segment Revenues 1Q14 12/28/13 Fiscal Year Q14 3/29/14 3Q14 6/28/14 4Q14 9/27/14 Full Year % of Revenue Share Cytology & Perinatal $121.6 $119.4 $122.7 $121.0 $ % Molecular Diagnostics * 478.8* 18.9% Blood Screening % Total Diagnostics $285.7 $290.8 $293.1 $317.2* $1,186.8* 46.9% Breast Imaging $178.0 $189.4 $192.7 $196.3 $ % Interventional Breast Solutions % Other % Total Breast Health $226.5 $238.7 $238.0 $241.5 $ % Surgical $78.9 $72.0 $78.5 $78.5 $ % Skeletal Health $21.4 $23.5 $23.0 $23.4 $ % Total Revenues $612.4 $625.0 $632.6 $660.6* $2,530.7* * Excluding the $20.1 million revenue benefit related to an amendment to the Company s license agreement with Roka Bioscience (all of which was in the U.S.), 4Q14 molecular diagnostics revenue would have been $117.2 million, total diagnostics revenue would have been $297.1 million, and total revenues would have been $640.5 million. Similarly, FY14 molecular diagnostics revenue would have been $458.7 million, total diagnostics revenue would have been $1,166.7 million, and total revenues would have been $ million. 34

35 Business Segments Revenue Detail (unaudited) $s in millions Fiscal Year Q15 12/27/14 2Q15 3/28/15 3Q15 6/27/15 4Q15 9/26/15 Full Year % of Revenue Share Business Segment Revenues Cytology & Perinatal $120.1 $113.3 $118.1 $120.8 $ % Molecular Diagnostics % Blood Screening % Total Diagnostics $304.1 $296.7 $306.9 $ , % Breast Imaging $197.5 $211.0 $ % Interventional Breast Solutions % Other % Total Breast Health $242.0 $255.5 $279.6 $286.3 $1, % GYN Surgical $84.4 $79.1 $ % Skeletal Health $22.3 $24.2 $ % Total Revenues $652.8 $655.5 $693.9 $702.8 $2,

36 Business Segments Revenue Detail (unaudited) $s in millions Fiscal Year Q16 12/26/15 2Q16 3/26/16 3Q16 6/25/16 4Q16 9/24/16 Year to Date % of Revenue Share Business Segment Revenues Cytology & Perinatal $120.4 $ % Molecular Diagnostics % Blood Screening % Total Diagnostics $310.7 $ % Breast Imaging $218.1 $ % Interventional Breast Solutions % Other % Total Breast Health $262.2 $ % GYN Surgical $98.8 $ % Skeletal Health $23.5 $ % Total Revenues $695.2 $

37 Reconciliation of GAAP to Non-GAAP (unaudited) $s in millions, except earnings per share Twelve Months Ended December 26, 2015 December 27, 2014 GROSS PROFIT GAAP gross profit $379.1 $338.6 Adjustments: Amortization of intangible assets $73.4 $73.9 Incremental depreciation expense Integration/consolidation costs Non-GAAP gross profit $453.0 $413.5 GROSS MARGIN PERCENTAGE GAAP gross margin percentage 54.5% 51.9% Impact of adjustments above 10.7% 11.4% Non-GAAP gross margin percentage 65.2% 63.3% OPERATING EXPENSES GAAP operating expenses $253.0 $235.1 Adjustments: Amortization of intangible assets (22.6) (27.8) Incremental depreciation expense (0.9) (0.6) Integration/consolidation costs (0.2) - Restructuring and divestiture charges (2.3) (8.0) Other (6.0) (0.2) Non-GAAP operating expenses $221.0 $198.5 OPERATING MARGIN GAAP income from operations $126.1 $103.5 Adjustments to gross profit as detailed above Adjustments to operating expenses as detailed above Non-GAAP income from operations $232.0 $215.0 Continued on next page 37

38 Reconciliation of GAAP to Non-GAAP (unaudited) $s in millions, except earnings per share Twelve Months Ended September 26, 2015 September 27, 2014 OPERATING MARGIN PERCENTAGE GAAP operating margin percentage 18.1% 15.9% Impact of adjustments above 15.3% 17.0% Non-GAAP operating margin percentage 33.4% 32.9% INTEREST EXPENSE GAAP interest expense $39.2 $52.5 Adjustments: Non-cash interest expense relating to convertible notes (6.4) (8.8) Non-GAAP interest expense $32.8 $43.7 PRE-TAX INCOME GAAP pre-tax earnings (loss) $114.7 $44.1 Adjustments to pre-tax earnings as detailed above Debt extinguishment loss Gain on sale of available-for-sale marketable security (25.1) - Unrealized gains on forward foreign currency contracts (1.0) - Non-GAAP pre-tax income $200.9 $171.1 NET INCOME GAAP net income $84.9 $29.2 Adjustments to GAAP net income (loss) as detailed above Income tax effect of reconciling items 2 Non-GAAP net income $135.1 $111.6 EARNINGS PER SHARE GAAP earnings per share Diluted $0.29 $0.10 Adjustments to net earnings (loss) (as detailed below) Non-GAAP earnings per share Diluted 1 $0.46 $0.39 ADJUSTED EBITDA Non-GAAP net income $135.1 $111.6 Interest expense, net, not adjusted above Provision for income taxes Depreciation expense, not adjusted above Adjusted EBITDA $252.0 $ Non-GAAP earnings per share was calculated based on: 289,537 and 278,360 weighted average diluted shares outstanding for the years ended September 26, 2015 and September 27, 2014, respectively. 2 To reflect an annual effective tax rate of 34.25% on a non-gaap basis for the year ended September 26, 2015 and 34.75% on a non-gaap basis for the year ended September 27,